Generic liquid drug manufacturer Pharmaceutical Associates, Inc. (PAI), has notified 340B covered entities on the U.S. Health Resources and Services Administration (HRSA) website about 340B overcharges and potential credit/rebill repayments regarding all of its products covering the first through third quarters of 2019.
A HRSA audit in fiscal year 2020 found that PAI charged more than the 340B ceiling price and had an incorrect record in 340B OPAIS, the 340B program database. HRSA required PAI to repay covered entities for the overcharges. PAI’s public notice to covered entities, dated Jan. 25, does not mention the audit.
Generic liquid drug manufacturer Pharmaceutical Associates, Inc. (PAI), has notified 340B covered entities on the U.S. Health Resources and Services Administration (HRSA) website about 340B overcharges and potential credit/rebill repayments regarding all of its products covering first through third quarters of 2019.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
